Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.